Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Erasca's Naporafenib, combined with trametinib, demonstrates potential for durable efficacy in NRAS-mutant melanoma, addressing a critical unmet need after frontline immunotherapy.
Erasca's naporafenib plus trametinib demonstrates a 40% response rate in NRAS-mutant melanoma patients in the Phase 1b SEACRAFT-1 trial.